| 查看: 1932 | 回复: 5 | |||
[交流]
【讨论】非索非那定的市场情况
|
|
求：非索非那定的 一、产品研发背景 1. 原研厂家 2. 研发时间与研究立意 3.国外的上市与销售情况 二、与现有竞争产品的比较 三、国内市场情况 1.批文数量及厂家（含规格） 2. 历史销售情况及分析 3.国内主要生产厂家的销售情况 |
回复此楼» 猜你喜欢
胰岛素的实验室表达
已经有1人回复
-
胰岛素的实验室表达
已经有0人回复
-
药物学论文润色/翻译怎么收费?
已经有173人回复
-
胰岛素的实验室表达
已经有0人回复
-
求助电子版：晶型药物研发理论与应用
已经有0人回复
-
NSCLC脑转移肿瘤模型
已经有0人回复
-
CHP-134这个细胞系哪里有？
已经有0人回复
-
北京大学药学院诚招药物化学/有机化学方向博士后
已经有6人回复
-
2027药学博士申请
已经有1人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 现在国内有那几家在生产毒莠定？市场情况如何？
已经有4人回复
2楼2011-03-18 12:51:27
★ ★ ★
warlen(金币+1): 谢谢参与 2011-03-18 15:54:09
空城若虚(金币+40): 非常感谢！ 2011-03-18 20:13:20
caoyuan521(金币+2): 谢谢参与！ 2011-03-18 21:04:15
warlen(金币+1): 谢谢参与 2011-03-18 15:54:09
空城若虚(金币+40): 非常感谢！ 2011-03-18 20:13:20
caoyuan521(金币+2): 谢谢参与！ 2011-03-18 21:04:15
|
Fexofenadine hydrochloride Cas number: 153439-40-8, 138452-21-8 - General description: Fexofenadine (trade names Allegra, Telfast, Fastofen, Tilfur, Vifas, Telfexo, Allerfexo) is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine (trade names include Triludan and Seldane), an antihistamine which caused QT interval prolongation, potentially leading to cardiac arrhythmia. It has been described as both second-generation[3] and third-generation antihistamine. The older antihistaminic agent terfenadine was found to metabolize into the related carboxylic acid, fexofenadine. Fexofenadine was found to retain all of the biological activity of its parent while giving fewer adverse reactions in patients, so terfenadine was replaced in the market by its metabolite.[8] Fexofenadine was originally synthesized in 1993 by Massachusetts-based biotechnology company Sepracor, which then sold the development rights to Hoechst Marion Roussel (now part of Sanofi-Aventis), and was later approved by the Food and Drug Administration (FDA) in 1996. AMRI holds the patents to the intermediates and production of fexofenadine HCl along with Roussel. Since that time, it has achieved blockbuster drug status with global sales of $1.87B USD in 2004 (with $1.49B USD coming from the United States). AMRI received royalty payments from Aventis that enabled the growth of AMRI. On January 25, 2011, the FDA approved over-the-counter sales of fexofenadine in the United States, with Sanofi-Aventis' version expected to become available on March 4, 2011. I. Originator:Aventis Pharma, Sepracor; Marketer: ViroPharma; Reference patent: JP 1996502022; WO 9321156; II. Main Competitors in U.S: N021963 Yes FEXOFENADINE HYDROCHLORIDE SUSPENSION; ORAL 30MG/5ML ALLEGRA SANOFI AVENTIS US -------------------------------------------------------------------------------- A076191 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 180MG FEXOFENADINE HYDROCHLORIDE BARR -------------------------------------------------------------------------------- A076191 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 30MG FEXOFENADINE HYDROCHLORIDE BARR -------------------------------------------------------------------------------- A076191 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 60MG FEXOFENADINE HYDROCHLORIDE BARR -------------------------------------------------------------------------------- A076502 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 180MG FEXOFENADINE HYDROCHLORIDE DR REDDYS LABS LTD -------------------------------------------------------------------------------- A076502 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 30MG FEXOFENADINE HYDROCHLORIDE DR REDDYS LABS LTD -------------------------------------------------------------------------------- A076502 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 60MG FEXOFENADINE HYDROCHLORIDE DR REDDYS LABS LTD -------------------------------------------------------------------------------- A077081 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 180MG FEXOFENADINE HYDROCHLORIDE MYLAN -------------------------------------------------------------------------------- A077081 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 30MG FEXOFENADINE HYDROCHLORIDE MYLAN -------------------------------------------------------------------------------- A077081 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 60MG FEXOFENADINE HYDROCHLORIDE MYLAN -------------------------------------------------------------------------------- A076447 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 180MG FEXOFENADINE HYDROCHLORIDE TEVA -------------------------------------------------------------------------------- A076447 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 30MG FEXOFENADINE HYDROCHLORIDE TEVA -------------------------------------------------------------------------------- A076447 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 60MG FEXOFENADINE HYDROCHLORIDE TEVA -------------------------------------------------------------------------------- A076236 AB No FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE TABLET, EXTENDED RELEASE; ORAL 60MG;120MG FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE BARR -------------------------------------------------------------------------------- A079043 No FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE TABLET, EXTENDED RELEASE; ORAL 180MG;240MG FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE DR REDDYS LABS LTD -------------------------------------------------------------------------------- A076298 AB No FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE TABLET, EXTENDED RELEASE; ORAL 60MG;120MG FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE IMPAX PHARMS III. China Domestic Market I suggest you to look through the SFDA website to get related informations. It is not difficult. IV. The market information is not easy to acquire. I suggest you to purchase IMS data or BMI data. |
3楼2011-03-18 13:36:14
4楼2011-03-18 20:10:17
我主要是为了赚BB5楼2011-03-18 21:35:10
6楼2011-03-29 08:47:19